Company improves 2026 GAAP operating expense outlook by $0.2 bln from previous estimate
Moderna expects 2026 year-end cash balance of $4.7-5.2 bln, up $0.2 bln from prior estimate
Result drivers
COVID VACCINE SALES - Lower COVID vaccine sales in the U.S. and South America weighed on revenue, per co statement
MANUFACTURING EFFICIENCY - Cost of sales decreased due to improved manufacturing productivity and operational efficiencies, per co statement
R&D SPENDING - Research and development expenses declined due to lower clinical development costs after wind-down of late-stage programs, per co statement
Analyst coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 17 "hold" and 3 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Moderna Inc is $45.00, about 22.3% below its July 30 closing price of $57.92
MRNA•
